1 Activated NK Cells with Pro-inflammatory Features are Associated with Atherogenesis in

2 **Perinatally HIV-Acquired Adolescents**

3

4	Mario Alles ^{1#} , Manuja Gunasena ¹	^{1,2 #} , Aaren Kettelhut ³ ,	Kate Ailstock ³ , \	Victor Musiime ⁴ , Cissy Kityo ⁴ ,
---	--	---	--------------------------------	--

5 Brian Richardson⁵, Will Mulhern¹, Banumathi Tamilselvan⁶, Michael Rubsamen⁶, Dhanuja

6 Kasturiratna⁷, Thorsten Demberg⁸, Cheryl M. Cameron⁶, Mark J. Cameron⁵, Sahera Dirajlal-Fargo⁹,

- 7 Nicholas T. Funderburg³ and Namal P.M. Liyanage^{1,2*}
- 8
- ⁹ ¹ Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University,
- 10 Columbus, OH, USA, ² Department of Veterinary Biosciences, College of Veterinary Medicine, The
- 11 Ohio State University, Columbus, OH, USA, ³ School of Health and Rehabilitation Sciences, College
- 12 of Medicine, The Ohio State University, Columbus, OH, USA, ⁴Joint Clinical Research Center,
- 13 Kampala, Uganda, ⁵Department of Population and Quantitative Health Sciences, School of
- ¹⁴ Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA. ⁶Department
- 15 of Nutrition, School of Medicine, Case Western Reserve University School of Medicine, Cleveland,
- 16 OH, USA. ⁷ Department of Mathematics and Statistics, Northern Kentucky University, KY, Highland
- 17 Heights, KY, USA.⁸Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
- ¹⁸ ⁹Northwestern Feinberg School of Medicine, Chicago, IL USA.
- 19
- 20 # equally contributed
- 21 *Corresponding author:
- 22 Namal P.M. Liyanage
- 23 Assistant Professor
- 24 788 Biomedical Research Tower
- 25 460 W 12th Ave, Columbus OH 43210
- 26 Phone: 614 293 9114
- 27 E-Mail: namal.liyanage@osumc.edu
- 28
- 29
- 30

31 Abstract:

Human immunodeficiency virus (HIV) is associated with persistent immune activation and 32 33 dysfunction in people with HIV despite treatment with antiretroviral therapy (ART). Modulation of the 34 immune system may be driven by: low-level HIV replication, co-pathogens, gut dysbiosis 35 /translocation, altered lipid profiles, and ART toxicities. In addition, perinatally acquired HIV (PHIV) 36 and lifelong ART may alter the development and function of the immune system. Our preliminary 37 data and published literature suggest reprogramming innate immune cells may accelerate aging 38 and increase the risk for future end-organ complications, including cardiovascular disease (CVD). 39 The exact mechanisms, however, are currently unknown. Natural killer (NK) cells are a highly 40 heterogeneous cell population with divergent functions. They play a critical role in HIV transmission 41 and disease progression in adults. Recent studies suggest the important role of NK cells in CVDs; 42 however, little is known about NK cells and their role in HIV-associated cardiovascular risk in PHIV 43 adolescents. Here, we investigated NK cell subsets and their potential role in atherogenesis in PHIV 44 adolescents compared to HIV-negative adolescents in Uganda. Our data suggest, for the first time, 45 that activated NK subsets in PHIV adolescents may contribute to atherogenesis by promoting 46 plasma oxidized low-density lipoprotein (Ox-LDL) uptake by vascular macrophages. 47 48 49 50 51 52 53 54 55 56

57 Introduction:

58 HIV remains a significant public health challenge, particularly in pediatric and adolescent 59 populations. According to the Joint United Nations Program on HIV/AIDS (UNAIDS), there were an 60 estimated 1.5 million children (aged 0-14 years) and 1.1 million adolescents (aged 15-19 years) 61 living with HIV globally in 2022 (UNAIDS, 2023 estimates). The majority (almost 86%) of these 62 children reside in the Sub-Saharan African region where the primary mode of transmission for those 63 under 15 years of age is perinatal transmission (1). With access to ART, however, these children 64 are able to live well into adulthood (2). HIV and its treatment with ART are associated with 65 persistent immune activation and immune dysfunction (3). This may be driven by low level HIV 66 replication, co-pathogens, gut microbial translocation and ART toxicity (4). This persistent immune 67 dysregulation may be a culprit in the increased incidence of non-AIDS related co-morbidities 68 including cardiovascular diseases, neurocognitive disorders, and cancer (5-9). CVD is the most 69 common cause of morbidity and mortality in people living with HIV (PLWH) (6, 10-13) and has been 70 found to be up to three times more common in these individuals when compared to those without 71 HIV (14, 15). Specifically, PLWH have higher rates of coronary artery disease and atherosclerosis, 72 an asymmetrical focal thickening of the intima of arteries with lipid plague, which can result in 73 myocardial infarction (16). So far, the primary immune cells linked to the inflammatory process 74 surrounding atherosclerotic plague development, or atherogenesis, are monocytes/macrophages 75 (17). Other immune cells, including T lymphocytes likely contribute to this phenomenon, and the 76 characterization of immune cell contributions to atherogenesis could have significant therapeutic 77 implications (18-20). 78 NK cells are a group of innate lymphoid cells that are important in the surveillance and clearance of 79 viral infections and play a key role in the immunopathogenesis of HIV (21, 22). NK cells are critical

80 mediators of the innate immune response and are especially important in the pediatric population,

- 81 where they take precedence during pathogen challenge over a still-developing adaptive immune
- 82 response in early childhood (23). Even though traditionally thought to be immune cells with purely

83 innate immune features, there is now mounting evidence that human NK cells display features of 84 antigen specificity and memory, as depicted by their vaccination-dependent antigen-specific recall 85 responses (24). Such "recall responses" may be related to a recent concept known as trained 86 immunity, where innate immune cells are epigenetically reprogrammed to respond differently on 87 subsequent exposure to a microbial product. Trained immunity can be induced by microbial 88 products such as lipopolysaccharide and $1,3-\beta$ -D-glucan, which frequently enter the blood stream 89 because of increased gut permeability in PLWH (25). 90 NK cells can be classified into different subtypes based on the relative expression of CD56 and 91 CD16 receptors and by their different functional capabilities, with higher expression of CD56 signifying increased cytokine producing potential (CD56^{bri}CD16^{dim/-}), and higher expression of CD16 92 93 (CD56^{dim/-}CD16^{bri}) reflecting more cytotoxic capabilities (26). Among these subpopulations, varying 94 degrees of expression of activating (e.g., CD69, CD57, NKp44, HLA-DR) and inhibitory (e.g., 95 NKG2A) receptors and cytokine/chemokine receptors (e.g., CCR5, CXCR3, CXCR5) determine 96 their functional and migratory characteristics (27). 97 Studies have demonstrated that HIV differentially affects protein expression among several NK cell 98 subsets (26). A study among a cohort of neonates in Botswana with perinatally acquired HIV revealed that CD57⁺CD56^{dim}CD16^{dim}NK cells, cells with elevated antiviral and cytotoxic properties, 99 100 increased over time following birth (28). This increase correlated negatively with the frequency of 101 intact proviruses, signifying that this subpopulation of cells played a role in reducing HIV-1 reservoir 102 cells (29). Furthermore, among PLWH, these activated cytotoxic cells can express chemokine 103 receptors like CCR5 and CXCR4 through trogocytosis, thereby enhancing their pro-inflammatory 104 potential (30). 105 While substantial evidence exists regarding the significance of NK cell subsets in HIV among adults 106 and children, a research gap exists in understanding their role in adolescents with PHIV exposed to 107 HIV and/or ART since birth. Emerging concerns suggest that HIV's impact on adolescents may 108 surpass that in adults due to heightened inflammation and prolonged immune activation. This

109	sustained immune dysregulation in PHIVs may be dominated by NK cells with altered phenotypic
110	and functional characteristics. Given the role of NK cells in atherosclerosis (31), we hypothesize
111	that persistent NK cell activation/alteration in PHIV may contribute to atherogenesis in PHIVs. In
112	this study, we found that PHIV adolescents exhibit activated and pro-inflammatory NK cell profiles
113	associated with HIV, which directly influence Ox-LDL uptake by macrophages, driving foam cell
114	(lipid-laden macrophages) formation and atherogenesis. Additionally, we identify NKG2D/ligand
115	interaction as a potential mediator of this mechanism. These findings highlight novel therapeutic
116	and preventive targets to mitigate cardiovascular disease risk in this patient group.
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	

135 **Result**:

136 Study design and cohort demographics. For our analysis, we used cryopreserved peripheral 137 blood mononuclear cells (PBMC) and plasma samples obtained from two groups: adolescents living 138 with perinatally acquired HIV (PHIV) (n=18) and a group of age- and sex-matched adolescents 139 unexposed and HIV negative (HIV-, n=20). These specimens were collected during a study 140 conducted at the Joint Clinical Research Center (JCRC) in Kampala, Uganda, between 2017 and 141 2021 as previously described(32, 33). Both PHIV and HIV- adolescents were prospectively enrolled 142 in this observational cohort study. Overall, the mean age was 14 years (SD=1.7), 52 % were 143 females, and 94% PHIV participants had undetectable viral load (<50 copies/mL). Amongst PHIVs, 144 about 53% were on a dolutegravir-based regimen, the remaining were on nevirapine, efavirenz or 145 the boosted protease inhibitor lopinavir/ritonavir due to the ongoing transition to the newer WHO 146 ART guidelines at the time of the participant enrollment (34). We did not observe any significant 147 differences in CMV seropositivity between the two groups (Table 1). No significant differences were 148 also observed in the routinely measured serum lipids, including cholesterol, high-density lipoprotein, 149 low-density lipoprotein, very low-density lipoprotein, and triglycerides between PHIVs and HIV-150 (Table 2).

151

152 NK cells in HIV-unexposed adolescents show high receptor diversity. To determine the impact 153 of HIV on NK cell subsets in PHIV, we first examined cell populations among HIV-unexposed 154 adolescents using high-dimensional spectral flow cytometry in conjunction with conventional flow 155 cytometry analysis (Supplemental Figure 1A). Additionally, we utilized FlowSOM-based automatic 156 clustering algorithms, and Uniform Manifold Approximation and Projection (UMAP) for dimensional 157 reduction visualization (Figure 1A). This analysis was conducted on CD45⁺ CD3⁻ CD19⁻ cells to 158 discern NK cell clusters and subsets within the cohort. We next conducted a clustered heatmap 159 analysis (Figure 1B), revealing the presence of eight distinct NK cell clusters and two monocyte cell 160 clusters. Furthermore, when applying the previously described gating strategy based on CD56 and

161 CD16 expression to identify NK cells in neonates (28), we identified six distinct NK cell subsets in HIV- adolescents (Figure 1C); the prominent NK cell population in the blood of adolescents without 162 HIV was CD56^{dim}CD16^{dim}, followed by CD56⁻CD16^{dim}, and CD56^{dim}CD16⁻ (Figure 1D). CD16⁺ NK 163 164 subsets displayed a more activated phenotype, with increased expression of activation markers 165 such as HLA-DR (Figure 1H) (35). In contrast, the CD56⁺ NK subsets showed a more inhibitory 166 phenotype, marked by elevated expression of the inhibitory marker NKG2A (Figure 1K) (36). 167 Additionally, we observed significantly increased CD27 expression (Figure1G) among CD56^{bri} NK 168 subsets, specifically CD56^{bri}CD16⁻ and CD56^{bri}CD16^{lo} subsets, indicating their importance in 169 mediating NK cell/T cell interaction via the CD27-CD70 pathway (37). CXCR3 expression (Figure 1E) was notably higher in the CD56 CD16^{dim} population compared to other subsets suggesting that 170 171 this subset has a greater potential for homing into inflamed tissue(38). The memory/maturity marker 172 CD57 (Figure 1L) was elevated in the CD56^{dim}CD16^{dim} cell subset. Importantly, we did not observe 173 differences in CCR5, CXCR5, CCR7, CD69, NKp44 and PD-1 expression among different NK cell 174 subsets in HIV- adolescents.

175

176 Differential expression of immune markers on NK cell subsets in PHIV adolescents. Next, we 177 compared NK cell phenotypes between PHIV adolescents and HIV- adolescents. Surprisingly, we 178 did not discern any substantial differences in the relative representation of NK subsets between 179 PHIV adolescents and their HIV- counterparts (Figure 2A). Nevertheless, when comparing the two 180 groups, we did observe significant variations in the expression levels of multiple cell surface 181 immune markers within NK cell subsets (Figure 2B-D). Significantly increased levels of surface 182 receptors CD57, CXCR3, and NKp44 were observed within the CD56^{dim}CD16^{dim} NK cell subset in 183 PHIV adolescents compared to their healthy counterparts (Figure 2E-G). In contrast, expression of 184 CD69 and HLA-DR were elevated on the CD56^{dim}CD16⁻ NK cell subset in the PHIV group 185 compared to expression on cells from the HIV- group (Figure 2H-I). These findings collectively 186 indicate an overall activated phenotype of these NK cell subsets in PHIV. Notably, the

187 CD56^{dim}CD16^{dim} NK subset within the PHIV group exhibited numerous alterations in the surface
 188 expression of immune markers compared to other NK cell subsets (Supplemental Figure 2).

189

190 Memory-like NK cell subset (CD57⁺) is highly present in PHIV adolescents compared to the 191 **HIV- group.** CD57⁺ memory-like NK cells have emerged as a critically important component in the 192 immune response to HIV. Furthermore, CD57 has been linked to cell adhesion and the acquisition 193 of homing molecules, notably CXCR1 and CX3CR1, the ligands for which are predominantly 194 expressed in inflamed peripheral tissues (39). In our study, we observed that among PHIV patients, 195 the CD56^{dim}CD16^{dim} NK cell subset exhibited higher levels of CD57 expression than other NK cell subsets (Figure 3A-C). Thus, we conducted a detailed analysis of the CD57⁺CD56^{dim}CD16^{dim} 196 197 population using conventional and high-dimensional data analysis approaches (Figure 3D-F). Our findings revealed that CXCR3 is markedly expressed in the CD57⁺CD56^{dim}CD16^{dim} NK cell subset 198 199 within the PHIV group when compared to levels in HIV adolescents (Figure 3G). This surprising 200 finding suggest that in PHIV, memory-like NK cells (CD57⁺CD56^{dim}CD16^{dim}) could possess the 201 ability to migrate to inflamed tissues.

202

203 Distinct relationships among cardiometabolic biomarkers, Ox-LDL, and NK cell subsets. 204 Next, we measured plasma biomarkers of immune activation and inflammation among study 205 participants. Although there were no statistically significant differences in the levels of many 206 biomarkers between groups (Figure 4A and Table 3), surprisingly, the plasma concentration of Ox-207 LDL was reduced among PHIVs compared to the plasma concentration of Ox-LDL in adolescents 208 without HIV (Figure 4B). Macrophages ingest Ox-LDL in the blood vessel wall, forming cholesterol-209 rich foam cells and initiating the development of atherosclerotic plaques. Pearson correlation 210 coefficient analysis showed significant correlations between NK cell subsets and Ox-LDL in PHIV 211 adolescents (Figure 4C). Notably, the memory-like NK cell subset (CD57⁺ CD56^{dim}CD16^{dim}), which 212 was increased in PHIVs (Figure 4D), exhibited robust negative correlations with Ox-LDL, providing

213 deeper insights into the complex relationship between memory-like NK cells and Ox-LDL. In

addition, although the frequency did not change in the PHIV cohort, a strong negative correlation

215 was observed between CCR5⁺ NK cell subsets (Figure 4E-H) and Ox-LDL levels, specifically within

the PHIV cohort.

217

218 Comprehensive transcriptomic profiling unveils differential regulation of innate immune and 219 lipid metabolism pathways. We conducted an in-depth transcriptomic analysis and identified 220 1638 differentially expressed genes (DEGs) in PBMCs obtained from PHIV and HIV- adolescents. 221 Among these statistically significant DEGs (p<0.05), 777 were upregulated, while 861 were 222 downregulated (Figure 5A and Supplemental Figure 4A and B). In terms of innate immune 223 activation, noteworthy upregulated DEGs included MYD88, TLR1, TLR2, CLEC4D, CLEC12B, 224 IRAK3, ITGB3BP, TNF, and CD163, while the expression profiles of GZMM and IL6R were 225 downregulated in PHIV. Additionally, we observed significant variations in gene expression 226 associated with immune cell migration to inflamed tissues, including upregulation of CXCL10, 227 ITGB3BP, and downregulation of ITGB7, CCR4, CXCR6, CXCR5, and CCR6. Our analysis also 228 revealed altered transcriptional profiles related to vascular wall remodeling involving genes like 229 S1PR1, FLT4, and COL18A1. Our flowcytometry analysis also revealed increased frequencies of 230 intermediate monocytes (Supplemental Figure 3A) among PHIVs (p<0.05) and this was partially 231 reflected through our transcriptome analysis that showed upregulated CD36 and CLEC10A, which 232 are known to be increasingly expressed in this subset of monocytes (40, 41). CD36 encodes for 233 the Ox-LDL receptor itself while COLEC12 (also found to be upregulated among PHIVs) mediates 234 the binding and internalization of Ox-LDL. Furthermore, our analysis predicted several epigenetic 235 modifications occurring in PBMCs of PHIV adolescents. This prediction was substantiated by the 236 high number of DEGs associated with histone modification and DNA methylation, exemplified by 237 genes like *HIST1H1C*, *HIST1H2AH*, and *HDAC1*. We conducted functional and pathway 238 enrichment analyses to ascertain the biological significance of these DEGs. Our gene ontology

239 analysis revealed a profound impact on vascular and lipid metabolism-related biological processes 240 involving immune cells among PHIV, including 'leukocyte adhesion to endothelial cells', 'NK cell 241 activation', 'NK cell degranulation', 'myeloid cell migration', 'myeloid cell differentiation', 'regulation 242 of lipid storage', 'regulation of lipid catabolism', and 'vascular wall remodeling' (Figure 5B and 243 supplemental Figure 5). Overall, the protein-protein interaction network analysis highlighted the 244 enrichment of pathways specifically related to innate immunity and epigenetic regulation (Figure 245 5C). Observed clustering based on the top differentially expressed genes and transcriptional 246 pathways (Supplemental Figure 6 A and B), underscores the phenotypical and functional 247 distinctions that exist between PHIV adolescents compared to HIV unexposed controls, offering 248 insights into the intricate transcriptional profiles shaping these differences.

249

250 Activated NK cell-mediated enhanced Ox-LDL uptake by monocyte-derived macrophages in-251 vitro. Based on our comprehensive analysis, we posit that in adolescents with PHIV, activated NK 252 cells, especially those expressing CCR5 or exhibiting memory-like characteristics, interact with 253 macrophages derived from blood monocytes, leading to enhanced uptake of Ox-LDL. It has been 254 documented that in established atherosclerosis, plasma levels of Ox-LDL correlate with levels 255 within established and saturated plaques (42). However, our results from an adolescent HIV 256 population with no known risk factors for atherosclerosis and less likelihood of plagues suggest 257 increased uptake of Ox-LDL by monocyte-derived macrophages from the bloodstream concurrently 258 reduces plasma Ox-LDL levels, the initiation of atherogenesis. We conducted an in vitro experiment 259 to examine the influence of activated NK cells on the uptake of Ox-LDL by macrophages (Figure 260 6A). We isolated NK cells from PBMCs of HIV- donors (n=5). These NK cells were externally 261 activated using IL-12, IL-15, and IL-18 (43). Concurrently, we induced the formation of autologous 262 monocyte-derived macrophages (MDMs) from peripheral blood monocytes by allowing PBMCs to 263 rest in Teflon-coated wells for up to six days, as described previously (44). After six days, we 264 incubated these MDMs in a medium containing commercially prepared Dil-labeled Ox-LDL for four

265 hours, in the presence and absence of activated autologous NK cells. We employed spectral flow 266 cytometry analysis to measure the uptake of Dil-Ox-LDL. In all donor samples tested, we observed 267 significantly higher Dil-Ox-LDL uptake in the presence of activated NK cells (Wilcoxon signed-rank 268 test; p<0.001 for all) (Figure 6B and C). To further investigate the role of activated NK cells in Ox-269 LDL uptake, we introduced blocking antibodies against NKG2D while co-culturing NK cells with 270 monocyte-derived macrophages (MDMs). This experiment revealed significantly reduced Ox-LDL 271 uptake in all tested samples in the presence of NKG2D blocking (p<0.001). These findings confirm 272 the role of activated NK cells in enhancing Ox-LDL uptake by MDMs and also suggest that the NK 273 cell receptor NKG2D may play an essential role in this process (Figure 6B and C). This adds to 274 previous reports of HIV-associated increased uptake of Ox-LDL in to MDMs associated with high 275 TNF- α levels, where TNF- α upregulates the NKG2D ligand, MICA, in the intimal tissue environment 276 (45, 46).

277

278 Methods

279 Study participants: This study took placed at the Joint Clinical Research Center (JCRC) in 280 Kampala, Uganda between 2017-2021 as previously described (32). Participants (PHIV and HIV-281 children) were prospectively enrolled in this observational cohort. All participants were 10-18 years 282 of age and as per Ugandan research guidelines, provided written informed assent. By design, 283 PHIV participants (n=18; median age =14.4 years) were on ART for at least 2 years with a stable 284 regimen for at least the last 6 months with HIV-1 RNA < 50 copies/mL. Self-reported co-infections 285 and malnutrition were exclusionary. Adolescents with pregnancy or intent to become pregnant were 286 excluded. The control group consisted of age/sex matched HIV-uninfected adolescents from the 287 same geographical location (n=20; median age=14.2 years) who had not been exposed to HIV in 288 utero. None of the participants were suffering from acute infection, malnutrition, were pregnant, had 289 active tuberculosis or diabetes mellitus, or were on anti-inflammatory or cholesterol lowering 290 medication at the time of sample collections.

291

Cell collection and processing: Participants were seen for blood draw obtained after an 8 hour fast. Plasma, serum, and PBMCs were cryopreserved and shipped to University Hospitals Cleveland Medical Center, Cleveland, Ohio. All assays were performed in batches and without prior thaw. For the purpose of this analysis, we included participants with plasma, serum and PBMCs available at the same time point.

297

298 Flow cytometry cell staining and analysis: We assessed innate and adaptive immune cell 299 surface markers in PHIV adolescents and HIV-uninfected controls. Cryopreserved PBMCs were 300 resuspended at 1–2 million cells per ml in R10 media (RPMI-1640 supplemented with 10% FBS 301 [fetal bovine serum], 2 mM l-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin) and 302 surface staining for flowcytometry was performed. Samples were stained with Fixability Viability Dye 303 (Zombie NIR Cat No. 423105) and incubated for 15 minutes. Cells were then washed, followed by 304 the addition of a surface antibody cocktail, the antibodies being previously titrated to determine the 305 optimal concentration (antibodies used in this study are listed in Table 4). After a 30-minute 306 incubation period cells were washed once again (All washing steps were carried out at 700g for 5 307 min at 4 °C). Following the filtering of cells through strainer capped FACS tubes, samples were 308 acquired on a Cytek Aurora flow cytometer. Spectral flow cytometry data were analyzed using 309 FlowJo software (Tree Star). We obtained "fluorescence minus 1" controls (cells stained with all 310 fluorochromes used in the experiment except 1) for each marker prior to spectral unmixing 311 (Supplemental Figure 1B).

312

Measurement of plasma biomarkers: The plasma collected from blood samples were stored at
 -80°C and batched until processing without a prior thaw. Then, using an enzyme-linked
 immunosorbent assay (ELISA), we measured the following inflammatory biomarkers in the plasma

of PHIV adolescents and uninfected controls: soluble CD14 (sCD14), C reactive protein (CRP),

- 317 oxidized low-density lipoprotein (Ox-LDL), 1,3-β-D glucan (BDG), soluble CD163 (sCD163),
- intestinal fatty acid binding protein (IFAB) and high-sensitivity interleukin-6 (hsIL6) (47).

319 Invitro assay for Ox-LDL uptake by monocyte-derived macrophages (MDMs): We conducted

320 an in vitro experiment to investigate the impact of activated NK cells on the uptake of Ox-LDL by

321 MDMs to substantiate our in vivo observations. Venous blood samples were collected in

322 heparinized tubes in order to isolate PBMCs via Ficoll gradient centrifugation. NK cells were then

323 isolated from these PBMCs through negative selection using the Miltenyi Biotec NK cell isolation kit

324 (130-092-657). Isolated NK cells were incubated invitro with IL-12, IL-15 and IL-18. Additional

325 PBMCs isolated from the same donor were rested and incubated in Teflon-coated wells for up to six

days, to induce differentiation of monocytes into macrophages (MDMs) (44). After six days, we

327 introduced these MDMs to a medium containing commercially manufactured Ox-LDL that had been

tagged with Dil dye to measure its uptake (10 ug/mL) into MDMs during a four-hour incubation

329 period both in the presence and absence of activated NK cells. Cells were washed twice with PBS,

and the intensity of Dil staining was measured by flow cytometry. To identify MDMs, CD45, CD3,

331 CD19, and CD14 surface immune markers were used. The above experiment was also carried out

in the presence of NKG2D and IFNγ blocking antibodies (added during the four-hour incubation

333 step with along with activated NK cells) on separate occasions to investigate the mechanism of NK

334 cell-influence on MDMs to impact their uptake of Ox-LDL.

335 **RNA Extraction and QC:** Cell viability was measured prior to RNA extraction for PBMC

336 samples using the Countess II FL Automated Cell Counter (ThermoFisher), and RNA extraction

337 was performed using the RNeasy mini kit (Qiagen). The quality of all RNA was determined using

the RNA integrity number as calculated from the Agilent Fragment Analyzer with the SS RNA assay

339 kit (Agilent) while the concentration was determined by NanoDrop (ThermoFisher).

Bulk RNA Sequencing: Total RNA prepared above was normalized to 100 ng input for library preparation with the TruSeq Stranded Total RNA with Ribo-Zero Globin kit (Illumina). The resulting libraries were assessed on the Agilent Fragment Analyzer with the HS NGS assay (Agilent) and quantified using the NEBNext® Library Quant Kit for Illumina® (New England Biolabs, Inc.) on an Applied Biosystems QuantStudio 7 Flex Real-Time PCR (ThermoFisher). Medium depth sequencing (30 million reads per sample) was performed with Novaseq (Illumina) on one SP flow cell as a 100 cycle paired-end run.

347

348 RNA-seg analysis : Raw demultiplexed fastg paired end read files were trimmed of adapters and 349 filtered using the program skewer (48) to throw out any with an average phred quality score of less 350 than 30 or a length of less than 10. Trimmed reads were then aligned using the STAR (49) aligner 351 to the Homo sapiens NCBI reference genome assembly version GRCh38 and sorted using 352 SAMtools (50). Aligned reads were counted and assigned to gene meta-features using the program 353 featureCounts (51) as part of the Subread package. These count files were imported into the R 354 programming language and were assessed for guality control, normalized and analyzed using an 355 in-house pipeline utilizing the limma voom method with quantile normalization (52) for differential 356 gene expression analysis. Gene set variation analysis was performed using the GSVA 357 Bioconductor library and the Molecular Signatures Database v5.0 (53, 54). Protein-protein 358 interaction visualizations were generated using Stringdb (55). Gene Ontology (GO) enrichment 359 analysis was performed to gain insights into the biological processes associated with a set of genes 360 of interest. The analysis was carried out using the clusterProfiler package in R (version 4.2.1). The 361 significance threshold for enriched GO terms was set at a p-value cutoff of 0.05, and the Benjamini-362 Hochberg method was applied for multiple testing correction using GO terms with a q-value 363 (adjusted p-value) below 0.05 were considered statistically significant. Cytoscape software (version 364 3.10.0) was used to visualize significant GO terms (56).

365 Statistical Analyses: Graphs and heatmaps were prepared using Graph Pad Prism (version 366 9.3.1), while dot plots, contour plots and t-SNE dimensionality reduction plots were generated using 367 FlowJo (version 10.8.2). Data were statistically analyzed using their bundled software. Statistical 368 comparisons involving more than two experimental groups were performed using ANOVA followed 369 by Tukey's multiple comparison test for pairwise comparisons. Comparisons between two groups 370 were performed using the Wilcoxon rank-sum test. To analyze the relationship between immune 371 signatures and plasma biomarkers, the Pearson correlation coefficient was calculated and plotted 372 on a correlogram using R 4.2.1. Scatter plots showing linear relationships between data were 373 created for significant correlations. 374

Study Approval: We obtained approval by the Research Ethics Committee in Uganda, University
Hospitals Cleveland Medical Center, Cleveland, Ohio and The Ohio State University. Caregivers
gave written informed consent.

378

379 **Discussion:** In this study we performed a comprehensive analysis of the major innate immune 380 cells (i.e., NK cells and monocytes) in a group of PHIV adolescents and HIV- age/sex matched 381 controls in Uganda. Our results demonstrated that several subsets of NK cells are activated (as 382 evidenced by their expression of CD69, CD57, NKp44 and HLA DR) in our PHIV cohort (Figure 2). Furthermore, in the PHIV cohort, subsets including CD56^{dim}CD16^{dim} NK cells had increased levels 383 384 of expression of CXCR3, granting them a greater potential to migrate to inflamed tissue, compared 385 to those in the HIV-uninfected adolescents. Our correlational analyses (Figure 4C-H) revealed a 386 negative association between plasma levels of Ox-LDL and many NK subsets expressing CD57 387 and the chemokine receptor CCR5, suggesting their involvement in the lowering of Ox-LDL in the 388 plasma compartment. This was confirmed by bulk RNA sequencing data of PBMCs which revealed 389 the enrichment of several DEGs and transcriptional pathways related to NK cell activation, innate

390 immune activation, and Ox-LDL metabolism. The direct influence of active NK cells in promoting 391 uptake of Ox-LDL by tissue macrophages was further supported by our in vitro studies (Figure 6). 392 NK cells have traditionally been considered as important mediators of anti-tumor(57) and anti-viral 393 (58) immunity. More recently, they have been also linked to various pathophysiological disease 394 processes including cardiovascular diseases(59). NK cells are known to be key players in 395 atherosclerosis(31), the most common pathophysiological condition associated with ischemic heart 396 disease. Most of the evidence on the involvement of NK cells in atherosclerosis has been derived 397 from observational studies conducted on plaque tissue using immunohistochemistry. Bonaccorsi et 398 al. studied phenotypic and functional characteristics of NK cells within the atherosclerotic plaque 399 environment and identified increased frequencies of CD56^{bri}perforin¹⁰ NK cells, expressing tissue-400 resident markers such as CD103, CD69 and CD49a, and producing increased amounts of 401 IFNγ(60).

402 Chronic HIV infection results in a persistent pro-inflammatory state in people living with HIV, even 403 during viral suppression by ART. Similar to previous studies(61), we too observed increased 404 activation among several NK subsets in the PHIV cohort. These cells had increased expression of 405 activation markers such as CD69, NKp44 and HLA-DR in many NK subpopulations, and bulk RNA-406 seq data confirmed upregulated transcription of signaling adaptors like MyD88 which is critical for 407 NK and other immune cell activation(62) along with enriched GO terms like 'NK cell activation 408 involved in immune response'.

We hypothesize that expression of the chemokine receptor CCR5 in these activated NK subsets in the PHIV population may signify a much greater potential of these cells to influence the pathogenesis of cardiometabolic disease. Compared to HIV- individuals, PLWH have been found to demonstrate significant arterial wall inflammation(63). During this inflammation, activated dendritic cells within vascular tissue secrete various chemokines such as RANTES/CCL5, CCL4, CX3CL1, CXCL10(64), and this has been supported by our transcriptome data. Particularly in the case of vascular inflammation surrounding atherogenesis, murine studies have demonstrated an

416 abundance of CCL5 and a high proportion of the chemokine receptor CCR5-expressing immune 417 cells in the atherogenic plaque microenvironment (65). Several activated and mature NK subsets 418 were observed among PHIV adolescents (as evidenced by their increased expression of activation 419 and maturation markers) that are pro-inflammatory in nature and express the chemokine receptor 420 CCR5 can potentially migrate towards vascular tissue that express the corresponding chemokine 421 CCL5 (66). It is likely that vascular tissue-homing activated, pro-inflammatory NK cells likely 422 express high levels of additional activating receptors like NKG2D on their surface (67). As 423 highlighted by our in vitro experiments, these cells may engage in NKG2D-mediated crosstalk with 424 vascular tissue-resident macrophages to promote their increased uptake of plasma Ox-LDL. The 425 strong negative correlation we observed between several of these increasingly activated NK 426 subsets among PHIVs expressing CCR5 and plasma Ox-LDL thus suggest a potential mechanism 427 that may contribute to the low plasma Ox-LDL levels observed among our PHIV cohort. This may 428 potentially result in the increased likelihood of atherogenesis among these individuals as opposed 429 to HIV- individuals.

430 Migration of blood monocytes into the blood vessel wall and the subsequent differentiation of these 431 cells into macrophages likely drives early stages of atherosclerotic plaque development (68). 432 Among these, CD14⁺CD16⁺ intermediate monocytes have been found to be the key monocyte 433 subset involved in atherogenesis (69). Justo-Junior et al. found that individuals with unstable angina 434 had higher numbers of intermediate monocytes in the circulation and that these expressed high 435 amounts of CCR2 which would mediate migration of these cells to inflamed vascular tissue 436 expressing their ligand MCP-1(70). Interestingly, we also found a significant increase in the levels of 437 circulating intermediate monocytes among our PHIV adolescents (Supplemental Figure 3), along 438 with the enriched GO terms involving mononuclear cell proliferation, differentiation and migration, 439 and we can only assume that the stage is slowly being set for the development and progression of 440 a pro-atherogenic state in these individuals beginning very early on in their lives.

441 Results from our in vitro studies indicate that NK cells influence uptake of Ox-LDL by macrophages 442 that in HIV, are more likely to migrate to inflamed vessel walls. Upon internalization of Ox-LDL using 443 scavenger receptors such as CD36, LOX-1 and SR-A, macrophages differentiate into foam cells 444 (71). The hypothesis that these macrophages actively interact with NK cells in the atherosclerotic 445 lesion has been under investigation, and is supported by the fact that ligands like 'major 446 histocompatibility complex class I chain-related (MIC)' (67) to the NK cell-activating receptor, 447 NKG2D, have been found to be expressed on foam cells derived from macrophages exposed to 448 Ox-LDL(72). Murine studies have shown that preventing NKG2D/ligand interaction suppresses 449 plaque formation in ApoE2/2 mice(73). However, since NKG2D has also been found on subsets of 450 T lymphocytes(67), T cells may also contribute to atherosclerotic plague formation in this manner 451 (as mentioned above). Our in vitro NKG2D blocking studies clearly demonstrate that NKG2D-452 mediated interactions between activated NK cells and macrophages increases macrophage uptake 453 of Ox-LDL. This further supports our correlational analysis between plasma Ox-LDL levels and 454 frequencies of activated NK cell subsets with migratory potential in our PHIV adolescents. 455 Interestingly we also reported upregulated transcription of CD36 in our PHIV cohort, which encodes 456 for the receptor mediating uptake of Ox-LDL into macrophages, further promoting plaque 457 generation. Indeed, in adults with HIV we have demonstrated increased expression of CD36 in 458 monocytes, suggesting that numerous mechanisms collectively contribute towards a proatherogenic 459 state among PHIVs (74). 460 It has been found that endogenous metabolites, such as Ox-LDL, that are abundant in the plaque 461 microenvironment, train the generation of pro-atherogenic monocytes and macrophages (25). 462 Dominant NK cell subsets in our PHIV cohort expressing high levels of memory markers like 463 CD57(39) indicates that exposure of these cells to a lipoprotein-rich microenvironment may trigger 464 trained immunity in these NK cells through epigenetic modification, similar to that seen in pro-465 atherogenic macrophages. Results from our bulk RNA-seq clearly demonstrate some degree of 466 epigenetic modifications occurring in the leukocytes of PHIV adolescents. In the case of

467 adolescents with HIV with no other dominant risk factors for cardiovascular disease, these trained

- 468 NK cells (either by persistent viral replication, gut microbial translocation, co-pathogens, ART and/or
- 469 Ox-LDL) may be considered as key innate immune cells involved in the ongoing progression of
- 470 atherogenesis, by interacting with pro-atherogenic macrophages.
- 471 In conclusion, we show that in PHIV adolescents, activated, pro-inflammatory NK cell phenotypes
- 472 associated with HIV infection may directly influence the uptake of circulating Ox-LDL by vessel wall-
- 473 resident macrophages and contribute to the development of atherogenesis. This is concerning and
- 474 may lead to increased risk of atherosclerotic CVD as these adolescents reach adulthood.
- 475 Furthermore, identification of the importance of the NKG2D/ligand interaction between NK cells and
- 476 macrophages in atherogenesis may represent valuable novel targets for both therapeutic and
- 477 prophylactic measures in mitigating cardiovascular disease in this patient population.
- 478

479 Acknowledgments

- 480 The authors gratefully acknowledge the support of all participants and their families. We thank
- 481 Wendy Lin and the staff of the CWRU Applied Functional Genomics Core for their technical
- 482 assistance with the RNA sequencing. This work was supported by National Institutes of Health
- 483 (NIH/NIAID) grant U01 AI168630-01.

484

485 **Data Availability**

486 The data supporting the findings of this study are available upon request from the corresponding

487 author. Data sharing is subject to ethical considerations and compliance with institutional policies.

488

489

490 **Author Contribution**:

491 M.A, M.G. performed experiments, data analysis and wrote the manuscript, A.K, K.A, performed

492 experiments, V.M. C.K performed sample collections, B.R., B.T., M.R., W.L performed experiments,

493	transcriptome data analysis, D.K., supervised data analysis, T.D. provided intellectual input and		
494	study design, C.C. M.C performed transcriptome data analysis, S.D.F, N.F and N.L designed the		
495	study and wrote the manuscript.		
496			
497			
498	Refer	ence:	
499			
500	1.	Global and regional trends. https://data.unicef.org/topic/hivaids/global-regional-trends/.	
501		Updated July 2023 Accessed October 31 2023, 2023.	
502	2.	Flynn PM, and Abrams EJ. Growing up with perinatal HIV. AIDS. 2019;33(4):597-603.	
503	3.	Hileman CO, and Funderburg NT. Inflammation, Immune Activation, and Antiretroviral	
504		Therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93-100.	
505	4.	Gabuzda D, Jamieson BD, Collman RG, Lederman MM, Burdo TH, Deeks SG, et al.	
506		Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from	
507		the HIV ACTION Workshop. Pathog Immun. 2020;5(1):143-74.	
508	5.	Hsue PY, Deeks SG, and Hunt PW. Immunologic basis of cardiovascular disease in HIV-	
509		infected adults. J Infect Dis. 2012;205 Suppl 3(Suppl 3):S375-82.	
510	6.	Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection	
511		and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614-22.	
512	7.	Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated	
513		neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.	
514		Neurology. 2010;75(23):2087-96.	
515	8.	Chen CH, Chung CY, Wang LH, Lin C, Lin HL, and Lin HC. Risk of cancer among HIV-	
516		infected patients from a population-based nested case-control study: implications for cancer	
517		prevention. BMC Cancer. 2015;15:133.	

518	9.	Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection
519		is independently associated with frailty in middle-aged HIV type 1-infected individuals
520		compared with similar but uninfected controls. AIDS. 2016;30(2):241-50.
521	10.	Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al.
522		Characteristics, Prevention, and Management of Cardiovascular Disease in People Living
523		With HIV: A Scientific Statement From the American Heart Association. Circulation.
524		2019;140(2):e98-e124.
525	11.	Feinstein MJ, Steverson AB, Ning H, Pawlowski AE, Schneider D, Ahmad FS, et al.
526		Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women. J Am Heart
527		Assoc. 2018;7(21):e009985.
528	12.	Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, et al.
529		Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection
530		Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the
531		Veterans Aging Cohort Study. JAMA Cardiol. 2017;2(5):536-46.
532	13.	Ho JE, and Hsue PY. Cardiovascular manifestations of HIV infection. Heart.
533		2009;95(14):1193-202.
534	14.	Kaplan RC, Hanna DB, and Kizer JR. Recent Insights Into Cardiovascular Disease (CVD)
535		Risk Among HIV-Infected Adults. Curr HIV/AIDS Rep. 2016;13(1):44-52.
536	15.	Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013;10(3):199-
537		206.
538	16.	Shrestha S, Irvin MR, Grunfeld C, and Arnett DK. HIV, inflammation, and calcium in
539		atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(2):244-50.
540	17.	Hsue PY, and Waters DD. HIV infection and coronary heart disease: mechanisms and
541		management. Nat Rev Cardiol. 2019;16(12):745-59.

- 18. Panigrahi S, Chen B, Fang M, Potashnikova D, Komissarov AA, Lebedeva A, et al. CX3CL1
- 543 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis. *PLoS Pathog.*
- 544 2020;16(9):e1008885.
- 545 19. Mudd JC, Panigrahi S, Kyi B, Moon SH, Manion MM, Younes SA, et al. Inflammatory
- 546 Function of CX3CR1+ CD8+ T Cells in Treated HIV Infection Is Modulated by Platelet
- 547 Interactions. *J Infect Dis.* 2016;214(12):1808-16.
- 548 20. Chen B, Morris SR, Panigrahi S, Michaelson GM, Wyrick JM, Komissarov AA, et al.
- 549 Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57(+) CD4 T
- 550 Cells in HIV Infection. *J Immunol.* 2020;204(10):2722-33.
- 551 21. Mikulak J, Oriolo F, Zaghi E, Di Vito C, and Mavilio D. Natural killer cells in HIV-1 infection
 552 and therapy. *AIDS*. 2017;31(17):2317-30.
- 553 22. Liyanage NP, Gordon SN, Doster MN, Pegu P, Vaccari M, Shukur N, et al. Antiretroviral
- 554 therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is
- altered by SIVmac(2)(5)(1) infection of macaques. *Virology*. 2014;450-451:359-68.
- 556 23. Singh A, Kazer SW, Roider J, Krista KC, Millar J, Asowata OE, et al. Innate Lymphoid Cell
- 557 Activation and Sustained Depletion in Blood and Tissue of Children Infected with HIV from
- 558 Birth Despite Antiretroviral Therapy. *Cell Rep.* 2020;32(11):108153.
- 559 24. Nikzad R, Angelo LS, Aviles-Padilla K, Le DT, Singh VK, Bimler L, et al. Human natural killer
 560 cells mediate adaptive immunity to viral antigens. *Sci Immunol.* 2019;4(35).

561 25. Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al.

- 562 Defining trained immunity and its role in health and disease. *Nat Rev Immunol.*
- 563 2020;20(6):375-88.
- 564 26. Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, et al. Human
- 565 CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset. *Front Immunol.*
- 566 2017;8:699.

567	27.	Bodduluru LN, Kasala ER, Madhana RM, and Sriram CS. Natural killer cells: the journey
568		from puzzles in biology to treatment of cancer. Cancer Lett. 2015;357(2):454-67.
569	28.	Garcia-Broncano P, Maddali S, Einkauf KB, Jiang C, Gao C, Chevalier J, et al. Early
570		antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and
571		induces a distinct innate immune profile. Sci Transl Med. 2019;11(520).
572	29.	Hartana CA, Garcia-Broncano P, Rassadkina Y, Lian X, Jiang C, Einkauf KB, et al. Immune
573		correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Rep.
574		2022;40(3):111126.
575	30.	Vo DN, Leventoux N, Campos-Mora M, Gimenez S, Corbeau P, and Villalba M. NK Cells
576		Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1. Vaccines (Basel).
577		2022;10(5).
578	31.	Palano MT, Cucchiara M, Gallazzi M, Riccio F, Mortara L, Gensini GF, et al. When a Friend
579		Becomes Your Enemy: Natural Killer Cells in Atherosclerosis and Atherosclerosis-
580		Associated Risk Factors. Front Immunol. 2021;12:798155.
581	32.	Dirajlal-Fargo S, Strah M, Ailstock K, Sattar A, Karungi C, Nazzinda R, et al. Persistent
582		immune activation and altered gut integrity over time in a longitudinal study of Ugandan
583		youth with perinatally acquired HIV. Front Immunol. 2023;14:1165964.
584	33.	Dirajlal-Fargo S, Zhao C, Labbato D, Sattar A, Karungi C, Longenecker CT, et al.
585		Longitudinal Changes in Subclinical Vascular Disease in Ugandan Youth With Human
586		Immunodeficiency Virus. Clin Infect Dis. 2023;76(3):e599-e606.
587	34.	. World Health Organization Update on the transition to dolutegravir-based antiretroviral
588		therapy. https://www.who.int/publications/i/item/9789240053335. Updated March 30 2022
589		Accessed October 31 2023, 2023.
590	35.	Erokhina SA, Streltsova MA, Kanevskiy LM, Grechikhina MV, Sapozhnikov AM, and
591		Kovalenko EI. HLA-DR-expressing NK cells: Effective killers suspected for antigen
592		presentation. J Leukoc Biol. 2021;109(2):327-37.

- 593 36. Kamiya T, Seow SV, Wong D, Robinson M, and Campana D. Blocking expression of
- 594 inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J Clin Invest.*
- 595 2019;129(5):2094-106.
- 596 37. Titanji K, Sammicheli S, De Milito A, Mantegani P, Fortis C, Berg L, et al. Altered distribution
- 597 of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic
- 598 human immunodeficiency virus-1 infection. *Immunology.* 2008;123(2):164-70.
- 599 38. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of 600 natural killer cells. *Immunol Rev.* 2007;220(1):169-82.
- 601 39. Kared H, Martelli S, Ng TP, Pender SL, and Larbi A. CD57 in human natural killer cells and
 602 T-lymphocytes. *Cancer Immunol Immunother.* 2016;65(4):441-52.
- 40. Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, et al. Gene expression profiling
- reveals the defining features of the classical, intermediate, and nonclassical human
 monocyte subsets. *Blood.* 2011;118(5):e16-31.
- 41. Thomas GD, Hamers AAJ, Nakao C, Marcovecchio P, Taylor AM, McSkimming C, et al.
- 607 Human Blood Monocyte Subsets: A New Gating Strategy Defined Using Cell Surface
- 608 Markers Identified by Mass Cytometry. *Arterioscler Thromb Vasc Biol.* 2017;37(8):1548-58.
- 42. Vickers KC, Maguire CT, Wolfert R, Burns AR, Reardon M, Geis R, et al. Relationship of
- 610 lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid 611 atherosclerosis. *J Lipid Res.* 2009;50(9):1735-43.
- 43. Granzin M, Wagner J, Kohl U, Cerwenka A, Huppert V, and Ullrich E. Shaping of Natural
- 613 Killer Cell Antitumor Activity by Ex Vivo Cultivation. *Front Immunol.* 2017;8:458.
- 614 44. Bowman ER, Cameron CM, Richardson B, Kulkarni M, Gabriel J, Cichon MJ, et al.
- 615 Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to
- 616 serum lipid profiles and activation indices: A model for studying atherogenic mechanisms.
- 617 *PLoS Pathog.* 2020;16(10):e1008869.

- 45. Maisa A, Hearps AC, Angelovich TA, Pereira CF, Zhou J, Shi MD, et al. Monocytes from
- 619 HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation
- 620 after transendothelial migration. *AIDS*. 2015;29(12):1445-57.
- 621 46. Chauveau A, Tonnerre P, Pabois A, Gavlovsky PJ, Chatelais M, Coupel S, et al. Endothelial
- 622 cell activation and proliferation modulate NKG2D activity by regulating MICA expression and
- 623 shedding. *J Innate Immun.* 2014;6(1):89-104.
- 47. Lake JE, Wang R, Barrett BW, Bowman E, Hyatt AN, Debroy P, et al. Trans women have
 worse cardiovascular biomarker profiles than cisgender men independent of hormone use
 and HIV serostatus. *AIDS*. 2022;36(13):1801-9.
- 48. Jiang H, Lei R, Ding SW, and Zhu S. Skewer: a fast and accurate adapter trimmer for next-
- 628 generation sequencing paired-end reads. *BMC Bioinformatics*. 2014;15:182.
- 49. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
 universal RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.
- 631 50. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
 632 Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9.
- Liao Y, Smyth GK, and Shi W. featureCounts: an efficient general purpose program for
 assigning sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923-30.
- 635 52. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
- 636 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.*
- 637 2015;43(7):e47.
- 638 53. Hanzelmann S, Castelo R, and Guinney J. GSVA: gene set variation analysis for microarray
 639 and RNA-seq data. *BMC Bioinformatics*. 2013;14:7.
- 640 54. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, and Mesirov JP.
 641 Molecular signatures database (MSigDB) 3.0. *Bioinformatics*. 2011;27(12):1739-40.


- 55. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING
- 643 v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic*
- 644 *Acids Res.* 2013;41(Database issue):D808-15.
- 56. Yu G, Wang LG, Han Y, and He QY. clusterProfiler: an R package for comparing biological
 themes among gene clusters. *OMICS*. 2012;16(5):284-7.
- 647 57. Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb
- Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK
 Cells. *Cell.* 2018;175(7):1731-43 e13.
- 550 58. Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang LS, et al. The RNA m6A reader YTHDF2
- 651 controls NK cell antitumor and antiviral immunity. *J Exp Med.* 2021;218(8).
- 52 59. Waters S, Lee S, Affandi JS, Irish A, and Price P. The effect of genetic variants affecting NK
- cell function on cardiovascular health and the burden of CMV. *Hum Immunol.* 2017;78(11-
- 654 **12**):747-51.
- 655 60. Bonaccorsi I, Spinelli D, Cantoni C, Barilla C, Pipito N, De Pasquale C, et al. Symptomatic
- 656 Carotid Atherosclerotic Plaques Are Associated With Increased Infiltration of Natural Killer
- 657 (NK) Cells and Higher Serum Levels of NK Activating Receptor Ligands. *Front Immunol.*658 2019;10:1503.
- 659 61. Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al.
- 660 Virologically suppressed HIV patients show activation of NK cells and persistent innate
 661 immune activation. *J Immunol.* 2012;189(3):1491-9.
- 662 62. Dixon KJ, Siebert JR, Wang D, Abel AM, Johnson KE, Riese MJ, et al. MyD88 is an
 663 essential regulator of NK cell-mediated clearance of MCMV infection. *Mol Immunol.*664 2021;137:94-104.
- 665 63. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial
 666 inflammation in patients with HIV. *JAMA*. 2012;308(4):379-86.


- 667 64. Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, and Fitzgerald-Bocarsly P. Virally
- 668 stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and
- 669 NK cells. *J Leukoc Biol.* 2004;75(3):504-14.
- 670 65. Balistreri CR, Caruso C, Grimaldi MP, Listi F, Vasto S, Orlando V, et al. CCR5 receptor:
- 671 biologic and genetic implications in age-related diseases. Ann N Y Acad Sci.
- 672 **2007;1100:162-72**.
- 673 66. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique
- 674 subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by
- 675 chemokine receptor expression repertoire. *J Immunol.* 2001;166(11):6477-82.
- 676 67. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T
- 677 cells by NKG2D, a receptor for stress-inducible MICA. *Science*. 1999;285(5428):727-9.
- 678 68. Camici PG, Rimoldi OE, Gaemperli O, and Libby P. Non-invasive anatomic and functional 679 imaging of vascular inflammation and unstable plaque. *Eur Heart J.* 2012;33(11):1309-17.
- 680 69. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, et al. CD14++CD16+
- 681 monocytes independently predict cardiovascular events: a cohort study of 951 patients
- referred for elective coronary angiography. *J Am Coll Cardiol.* 2012;60(16):1512-20.
- 683 70. Justo-Junior AS, Villarejos LM, Lima XTV, Nadruz W, Jr., Sposito AC, Mamoni RL, et al.
- 684 Monocytes of patients with unstable angina express high levels of chemokine and pattern-685 recognition receptors. *Cytokine*. 2019;113:61-7.
- 686 71. Hansson GK, and Hermansson A. The immune system in atherosclerosis. *Nat Immunol.*687 2011;12(3):204-12.
- 688 72. Ikeshita S, Miyatake Y, Otsuka N, and Kasahara M. MICA/B expression in macrophage
 689 foam cells infiltrating atherosclerotic plagues. *Exp Mol Pathol.* 2014;97(1):171-5.
- Kia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi GP, et al. Immune activation resulting
 from NKG2D/ligand interaction promotes atherosclerosis. *Circulation*. 2011;124(25):2933-
- 692 **43**.

- 693 74. Zidar DA, Juchnowski S, Ferrari B, Clagett B, Pilch-Cooper HA, Rose S, et al. Oxidized LDL
- 694 Levels Are Increased in HIV Infection and May Drive Monocyte Activation. J Acquir Immune
- 695 Defic Syndr. 2015;69(2):154-60.


696

Α.





Β.



U.


CD16


cluster01: CD14+HLA-DR+CXCR3+ cluster02: CD56dimCD16dimCXCR3dim cluster03: CD56+CD16-CXCR3+ cluster04: CD14+CD69+CXCR3dim cluster05: CD56-CD16^{dim}CXCR3^{dim}CD69+NKp44+HLA-DR^{dim} cluster06: CD56dimCD16dimCD57dimCD69dimNKp44dim

I. CD56^{dim}CD16⁻ NK cells IV. CD56^{dim}CD16^{dim} NK cells


cluster07: CD56⁻CD16⁺CXCR3⁺HLA-DR^{dim} cluster08: CD57dimHLA-DRdim cluster09: CD56dimCD16dimCD57+CXCR3dim cluster10: CD56+CD16-CD57+CXCR3dim

II. CD56^{bri}CD16⁻ NK cells V. CD56⁻CD16^{bri} NK cells III. CD56^{bri}CD16^{lo} NK cells VI. CD56⁻CD16^{dim} NK cells





Α.





Total NK cells








Β.


























Figure.2



C.



tSNE_1

CXCR3

CD57⁺CD56^{dim}CD16^{dim} NK cells

Max

G.

mCD16dim

5

6

S


C


%

60₇

40-

20-






H.

NKG2A


Figure.3




Min.

CD56-CD16^{bri}

CD56-CD16dim CD56^{bri}CD16⁻




Pearso C relation ficient





medRxiv preprint doi: https://doi.org/10.1101/2023.11.06.23297580; this version posted November 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

C.

D.







C.